Sarepta Therapeutics, Inc. (SRPT) Institutional Ownership & Insider Trading

323 institutions reported holding Sarepta Therapeutics, Inc. shares in 13F filings for the quarter ended 2026-06-30, according to EquiReason's reading of their SEC filings. 2 insider trades on Form 4 since 2025-10-01.

Source: SEC EDGAR filings · figures as of 2026-06-30 · read by EquiReason

SRPTSarepta Therapeutics, Inc.Follow SRPT — free

Biotechnology · Healthcare

—

Price chart with a free account

Market cap: 1.9B
P/E TTM: —
Dividend yield: —
52-week: —
Next earnings: 4 Nov, in 11 days

Institutions · all 13F filers

quarter to 30 Jun 2026 · filers in both quarters

323 institutions held —% of the shares. Across filers that reported both quarters, shares held changed +5.2%.

Largest moves, shares (millions)

Institutional flow by quarter

net shares added or trimmed, millions · filers in both quarters

Quarter	Holders	Shares held, M	Change	Increased	New	Decreased	Closed
Jun 26	323	108	+5.2%	89	38	114	55
Mar 26	336	103	+13.9%	102	32	118	39
Dec 25	341	94	+7.1%	129	55	86	35
Sep 25	310	87	+6.3%	100	52	98	94
Jun 25	354	83	-4.4%	149	56	78	116
Mar 25	421	86	-0.8%	132	60	136	92
Dec 24	454	88	-0.6%	141	47	140	52
Sep 24	449	86	-6.9%	155	47	136	78

Sarepta Therapeutics, Inc. — questions

Who owns Sarepta Therapeutics, Inc. stock?: 323 institutions reported Sarepta Therapeutics, Inc. shares in 13F filings for the quarter ended 2026-06-30. The largest: BlackRock, Inc. (18.0%), STATE STREET CORP (8.4%), VANGUARD PORTFOLIO MANAGEMENT LLC (7.9%).
Are Sarepta Therapeutics, Inc. insiders buying or selling?: 2 insider trades on Form 4 since 2025-10-01; the full list, with dates, people and plan status, is on this page.

Every figure on this page comes from Sarepta Therapeutics, Inc.'s own SEC filings — see them on SEC EDGAR. Price data is licensed and shown only inside the product.

How these figures are read: methodology · EquiReason.

Important information. Figures on this page are taken from filings submitted to the U.S. Securities and Exchange Commission (SEC) and processed automatically by EquiReason. They may contain errors, omissions or delays, and EquiReason makes no representation or warranty as to their accuracy, completeness or timeliness. Always verify figures against the original filing on SEC EDGAR before relying on them.

This page is provided for general information and educational purposes only. It does not constitute investment, financial, legal or tax advice, and it is not a recommendation or an offer to buy, sell or hold any security. It does not take into account your objectives, financial situation or needs. Past performance does not guarantee future results; any reliance on this information is at your own risk. See our Disclaimer and Risk Disclosure.